{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349490","form_type":"8-K","ticker":"MPLT","cik":"0001770069","company_name":"MapLight Therapeutics, Inc.","filed_at":"2026-08-13T20:51:37+00:00","discovered_at":"2026-08-13T20:53:00.325896+00:00","generated_at":"2026-08-13T20:53:11.290877+00:00","sec_items":["1.01","2.02","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MapLight raises $150M PIPE, Q2 net loss $60.2M; ZEPHYR Phase 2 met primary endpoint","bullets":["$150M PIPE: 9,197,887 shares at $11.38/share plus pre-funded warrants for 3,983,168 shares; closes Aug 14, 2026","Q2 2026 net loss $60.2M vs $29.8M YoY; R&D $53.4M vs $26.8M; cash $351.3M at June 30, 2026","Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia met primary endpoint; Phase 3 ZEPHYR-2 topline expected 2028","Phase 2 VISTA trial in Alzheimer's disease psychosis enrolling; topline expected H2 2027; Fast Track designation","ML-004 Phase 2 IRIS missed primary endpoint in autism; showed improvement in adolescent irritability subgroup"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349490","json":"https://secwatch.observer/filing/0001193125-26-349490.json","markdown":"https://secwatch.observer/filing/0001193125-26-349490.md","text":"https://secwatch.observer/filing/0001193125-26-349490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/0001193125-26-349490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:53:11.290877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}